INTEG B Share Price Performance
SEK 7.24
-9.01 (-55.45%)
80.2% undervalued intrinsic discount
SEK 36.50
Fair Value
Price SEK 7.24
AnalystConsensusTarget SEK 36.50
Fair ValueSEK 36.50
Share Pricen/a
Integrum AB (publ) Stock Price
- 1 Narratives written by author
- 0 Comments on narratives written by author
- 2 Fair Values set on narratives written by author
INTEG B Community Narratives
AN
Fair Value SEK 36.5 80.2% undervalued intrinsic discount
Regulatory Hurdles And US Momentum Will Shape Market Outlook
0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
Regulatory Hurdles And US Momentum Will Shape Market Outlook
Key Takeaways Revenue growth and profitability are threatened by cost pressures, reimbursement risks, regulatory challenges, and reliance on a narrow product portfolio. International expansion and market share gains face sustainability concerns due to adoption hurdles, geopolitical barriers, and unpredictable healthcare spending.Read more
20
users have viewed this narrative0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
AN
SEK 36.5
80.2% undervalued intrinsic discount
Fair Value
Profit Margin
8.61%
Future PE
48.86x
Price in 2028
SEK 39.31
Trending Discussion
Recently Updated Narratives
AN
Regulatory Hurdles And US Momentum Will Shape Market Outlook
Fair Value: SEK 36.5 80.2% undervalued intrinsic discount
1 followerusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
Snowflake Analysis
Integrum AB (publ) Key Details
Last Reported Earnings
Jan 31, 2026
Next Reporting Earnings
Jun 04, 2026
- -1.42
- 67.78%
- -38.53%
- 0%
About INTEG B
- Founded
- 1990
- Employees
- 35
- CEO
- WebsiteView website
Integrum AB (publ) researches, develops, and sells various systems for bone-anchored prostheses. The company provides prostheses for the Rehabilitation of Amputees (OPRA) implant systems, a bone-anchored prostheses system based on osseointegration, where the prostheses are directly attached to the bone, avoiding the use of socket. The OPRA implant system offers protection to the patient by avoiding bone fractures from accidental loads. It also provides Neuromotus, a technology that is used for therapy to reduce phantom limb pain after an amputation. It sells its implant systems to hospitals, clinics, and orthopedists worldwide. The company was incorporated in 1990 and is headquartered in Mölndal, Sweden.
